Get the Stockscreener App
437.23
1.55%
-6.89
After Hours:
415.00
-22.23
-5.08%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $437.23, with a volume of 1.62M.
It is down -1.55% in the last 24 hours and up +12.10% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$444.12
Open:
$437.03
24h Volume:
1.62M
Relative Volume:
0.62
Market Cap:
$236.38B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
30.41
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+1.11%
1M Performance:
+12.10%
6M Performance:
+15.28%
1Y Performance:
+56.10%
1-Day Range:
$435.00
$441.85
1-Week Range:
$426.00
$445.81
52-Week Range:
$269.77
$447.03
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
437.23 | 234.49B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Seeks Korean Partners in AI Drug Discovery, Obesity - Seoul Economic Daily
Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar - TradingView
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal - Yahoo Finance
Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs - Zacks Investment Research
Amgen stock holds near 52-week high as major investors adjust positions - AD HOC NEWS
HighTower Advisors LLC Sells 4,063 Shares of Amgen Inc. $AMGN - MarketBeat
Analyst recommendations: Amgen, Broadcom, Lululemon, Palo Alto Networks… - marketscreener.com
Amgen Inc. (AMGN) Stock Analysis: Evaluating the Dividend Potential and Analyst Ratings in a Competitive Market - DirectorsTalk Interviews
Why Could Tuesday Reopening Put Amgen (NASDAQ:AMGN) in Focus? - Kalkine Media
California State Teachers Retirement System Buys 297,430,677 Shares of Amgen Inc. $AMGN - MarketBeat
Amundi Purchases 512,883 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock heads into the open after a 1.55% pullback - AD HOC NEWS
Amgen Inc. $AMGN Stake Boosted by Saudi Central Bank - MarketBeat
Nilsine Partners LLC Makes New Investment in Amgen Inc. $AMGN - MarketBeat
MW Advisory LLC Makes New $1.05 Million Investment in Amgen Inc. $AMGN - MarketBeat
TD Waterhouse Canada Inc. Sells 18,281 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Shares Sold Off Sen. Sheldon Whitehouse - MarketBeat
Should TEZSPIRE’s EoE Win and Cardiometabolic Data Shift Amgen’s (AMGN) Immunology Narrative? - simplywall.st
AMGEN Inc. (AMGN) Futures: Prices, Contracts & Specs - Stocktwits
Amgen Slides as Tavneos Regulatory Pressure Weighs on Sentiment - Quiver Quantitative
AMGN Maintained by Wells Fargo -- Price Target Raised to $435 - GuruFocus
Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market? - Yahoo Finance
Tudor Financial Inc. Sells 5,697 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by NEOS Investment Management LLC - MarketBeat
NWF Advisory Services Inc. Sells 4,116 Shares of Amgen Inc. $AMGN - MarketBeat
Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating - marketscreener.com
Concurrent Investment Advisors LLC Has $18.70 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Can Amgen (AMGN) Justify Its Valuation After TEZSPIRE Data And Raised Guidance? - simplywall.st
Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report? - Yahoo Finance
ESC: Amgen CMO flags Repatha 'inflection' amid new data on mortality benefit - Fierce Pharma
149,626 Shares in Amgen Inc. $AMGN Bought by Nykredit A S - MarketBeat
B. Metzler seel. Sohn & Co. AG Sells 4,539 Shares of Amgen Inc. $AMGN - MarketBeat
Is Amgen (AMGN) Reasonable Or Rich As Cash Flow Improves? - finance.yahoo.com
TEZSPIRE’s Positive EoE Phase 3 Results Could Be A Game Changer For Amgen (AMGN) - Yahoo Finance
Amgen Stock Signals Its Confidence. The Market Agrees. - Yahoo Finance
Three Amgen executives will present in a public webcast Sept. 10. - Stock Titan
Amgen pushes back as rare-disorder therapy Tavneos faces U.K. ban - Seeking Alpha
PYA Waltman Capital LLC Has $6.42 Million Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Pushes Back Against UK Tavneos Suspension As Study Data Scrutiny Continues Globally - insights.citeline.com
UK regulator suspends rare-disease drug Tavneos for new patients over unreliable data - Reuters
Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs - 24/7 Wall St.
Susquehanna Fundamental Investments LLC Acquires Shares of 19,066 Amgen Inc. $AMGN - MarketBeat
Why Is Amgen (AMGN) In Focus After New Repatha Survival Data? - simplywall.st
Global pharma companies that have publicly announced Trump drug pricing agreements - Reuters
Amgen Inc Non Surgical Weight Management SolutionsView xx6qVsa1t - akhmetovfoundation.org
Amgen Is Up 51% in a Year. Is It Too Late to Buy? - TIKR.com
Sigma Planning Corp Reduces Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen's Repatha cuts death risk by 20% in heart study (AMGN:NASDAQ) - Seeking Alpha
Hennessy Advisors Inc. Buys 7,070 Shares of Amgen Inc. $AMGN - MarketBeat
Van ECK Associates Corp Sells 4,827 Shares of Amgen Inc. $AMGN - MarketBeat
Benjamin Edwards Inc. Purchases 6,790 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):